Funding Integrity in Health Research Act

Summary#

This bill called the Follow the Science Act would limit the role of political appointees in the National Institutes of Health (NIH) and protect NIH grants and contracts from being cancelled or paused except for narrow reasons. Its broad goal is to keep scientific decisions and funding at NIH free from political influence.

• Main change: It defines “political employee” and bars most political appointees from working for or managing NIH programs (with three named exceptions: the NIH Director, the National Cancer Institute Director, and the ARPA‑H Director).
• Grant/award rules: It bars political employees from taking part in soliciting, reviewing, scoring, selecting, or awarding NIH grants, contracts, cooperative agreements, other transactions, or other funding.
• Protections for funded projects: NIH could not cancel, delay, or suspend a grant or similar agreement unless it issues written findings showing financial mismanagement, research fraud, debarment, or malfeasance, and then notifies two congressional committees within 30 days.
• Reporting: The NIH Director must report to Congress within 30 days of enactment on any participation by political employees in grant/award activities from January 20, 2021 to the enactment date.
• Scope: The bill also says its rules do not override certain other statutory requirements (it refers to other sections of law).

What it means for you#

• Political appointees and senior hires

  • Most political appointees could not be hired by NIH or take part in managing NIH programs. A few top directors are explicitly allowed to be political appointees.
  • Political employees who work for other federal agencies would still be allowed to participate in NIH activities if some other law requires their involvement.

• NIH career staff and managers

  • Career scientists and administrators would likely take on more of the management and decision roles that political appointees now sometimes fill.
  • NIH would need new procedures to ensure political employees do not participate in grant or management decisions.

• Researchers, universities, and grant recipients

  • Grants, contracts, and cooperative agreements would be harder for NIH to cancel or suspend without specific written findings of fraud, financial mismanagement, debarment, or malfeasance.
  • This could reduce the risk of abrupt funding interruptions for ongoing research projects.

• ARPA‑H and other research programs

  • The ban on political employee participation in awards also applies to the Advanced Research Projects Agency for Health (ARPA‑H).
  • ARPA‑H’s Director remains an allowed political appointee under the bill.

• Congress

  • The bill requires a quick report on past political employee participation in award activities. It also requires notification to two named congressional committees if NIH cancels or suspends a covered agreement after enactment.

Expenses#

No publicly available information.

• The bill requires a report to Congress within 30 days. Preparing that report may require staff time at NIH.
• The new rules would likely require NIH to set up or update administrative controls and documentation. This could cause additional staff time, legal review, and record-keeping costs, but no estimate is provided.
• If NIH has to produce formal written findings before suspending awards, there could be added legal and investigatory costs in cases where problems are suspected.

Proponents' View#

• The bill appears intended to keep scientific decisions and funding at NIH free from political interference.
• Supporters may argue this would protect researchers and institutions from abrupt or politically motivated funding changes.
• It could be seen as strengthening trust in NIH by limiting noncareer political influence over grant awards and program management.
• Protecting awarded funding unless there is clear evidence of fraud or financial mismanagement could promote continuity of long-term research projects.

Opponents' View#

• One concern is that the bill limits NIH flexibility to pause or change funding quickly in some situations that are not fraud or malfeasance, such as new safety concerns, policy shifts, or other administrative issues.
• The bill does not clearly define how “participation” by political employees is measured. This may create uncertainty about who can be involved in certain decisions.
• It may be unclear how the new rules interact with existing laws and oversight tools referenced in the bill (the text says it does not affect other specified statutory requirements).
• Requiring written findings before suspension could slow corrective action and raise legal and investigatory costs when problems are suspected but not yet fully proven.
• The bill exempts three director positions from the hiring ban, but it does not explain why those exceptions are needed or how they will be managed.